Abstract
During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.
Keywords: Centenarians, epigenetics, exceptional longevity, longevity syndrome.
Current Vascular Pharmacology
Title:The Challenges in Moving from Ageing to Successful Longevity
Volume: 12 Issue: 5
Author(s): Genovefa Kolovou, Nir Barzilai, Calogero Caruso, Ewa Sikora, Miriam Capri, Irene P. Tzanetakou, Helen Bilianou, Peter Avery, Niki Katsiki, George Panotopoulos, Claudio Franceschi, Athanase Benetos and Dimitri P. Mikhailidis
Affiliation:
Keywords: Centenarians, epigenetics, exceptional longevity, longevity syndrome.
Abstract: During the last decades survival has significantly improved and centenarians are becoming a fast-growing group of the population. Human life span is mainly dependent on environmental and genetic factors. Favourable modifications of lifestyle factors (e.g. physical activity, diet and not smoking) and healthcare (e.g. effective vascular disease prevention) have also increased human life span. Genetic factors contribute to the variation of human life span by around 25%, which is believed to be more profound after 85 years of age. It is likely that multiple factors influence life span and we need answers to questions such as: 1) What does it take to reach 100?, 2) Do centenarians have better health during their lifespan compared with contemporaries who died at a younger age?, 3) Do centenarians have protective modifications of body composition, fat distribution and energy expenditure, maintain high physical and cognitive function, and sustained engagement in social and productive activities?, 4) Do centenarians have genes which contribute to longevity?, 5) Do centenarians benefit from epigenetic phenomena?, 6) Is it possible to influence the transgenerational epigenetic inheritance (epigenetic memory) which leads to longevity?, 7) Is the influence of nutrigenomics important for longevity?, 8) Do centenarians benefit more from drug treatment, particularly in primary prevention?, and, 9) Are there any potential goals for drug research? Many definitions of successful ageing have been proposed, but at present there is no consensus definition. Such definitions may need to differentiate between “Longevity Syndrome” and “Exceptional Longevity”.
Export Options
About this article
Cite this article as:
Kolovou Genovefa, Barzilai Nir, Caruso Calogero, Sikora Ewa, Capri Miriam, Tzanetakou P. Irene, Bilianou Helen, Avery Peter, Katsiki Niki, Panotopoulos George, Franceschi Claudio, Benetos Athanase and Mikhailidis P. Dimitri, The Challenges in Moving from Ageing to Successful Longevity, Current Vascular Pharmacology 2014; 12 (5) . https://dx.doi.org/10.2174/1570161111666131219095114
DOI https://dx.doi.org/10.2174/1570161111666131219095114 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HDL as a Target for Glycemic Control
Current Drug Targets Editorial: Vascular Calcification, Cardiovascular Risk and microRNAs
Current Vascular Pharmacology Molecular Dissection of Renal Ischemia-Reperfusion: Oxidative Stress and Cellular Events
Current Medicinal Chemistry Antisense Therapy for Cardiovascular Diseases
Current Pharmaceutical Design Non-Infectious Complications of Immunosuppressant Medications in Renal Transplant Patients
Current Clinical Pharmacology Current Therapeutic Approaches for Targeting Inflammation in Depression and Cardiovascular Disease
Current Drug Metabolism Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Anti-Seizure Medications and Estradiol for Neuroprotection in Epilepsy: The 2013 Update
Recent Patents on CNS Drug Discovery (Discontinued) Guidelines and their Implementation: A Discussion Document Focused on the Best Approaches to Drive Improvement
Vascular Disease Prevention (Discontinued) The Prothrombotic State in Hypertension and the Effects of Antihypertensive Treatment
Current Pharmaceutical Design A Systems Medicine Clinical Platform for Understanding and Managing Non- Communicable Diseases
Current Pharmaceutical Design Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris
Current Drug Safety The Role of Endogenous H2S in Cardiovascular Physiology
Current Pharmaceutical Biotechnology Preface [Hot Topic: The Roller Coaster of Antioxidant Therapy (Guest Editor: Francesco Visioli)]
Current Medicinal Chemistry Long Term Complications in Pediatric Liver Transplant Recipients: What Every Pediatrician Should Know
Current Pediatric Reviews Secondary Stroke Prevention in Patients with Cryptogenic Stroke and Patent Foramen Ovale
Vascular Disease Prevention (Discontinued) Total Antioxidant Capacity, Reducing Power and Cyclic Voltammetry of Zilla Macroptera (Brassicaceae) Aqueous Extract
Current Bioactive Compounds Novel Methods of Genetic Modification of Human Pluripotent Stem Cells
Recent Patents on Regenerative Medicine DASH Dietary Pattern: A Treatment for Non-communicable Diseases
Current Hypertension Reviews